Science Commons' mission is to speed the translation of basic research to useful discoveries. CollabRx has partnered with Science Commons, the Public Library of Science (PLoS), and CommerceNet to form Health Commons. Health Commons aims at bringing the same efficiencies to human health that the network brought to commerce. An introduction and overview is provided in the white paper, Health Commons: Therapy Development in a Networked World , co-authored by Marty Tenenbaum, Chairman and Chief Scientist at CollabRx, and John Wilbanks, Vice President of Science at Creative Commons.

FasterCures is dedicated to saving lives by saving time. Their mission is to identify and implement global solutions to accelerate the process of discovery and clinical development of new therapies for the treatment of deadly and debilitating diseases.

NIH Chemical Genomics Center (NCGC) was established by the National Institutes of Health (NIH) to create a national resource in chemical probe development. Their mission is to apply the tools of small molecule screening and discovery to the development of chemical probe research tools, for use in the study of protein and cell functions, and biological processes relevant to physiology and disease.

Public Library of Science (PLoS) is a nonprofit organization of scientists and physicians committed to making the world's scientific and medical literature a freely available public resource. CollabRx is partnering with PLoS, Science Commons, and CommerceNet on the Health Commons initiative which aims to change the way basic science is translated into the understanding and improvement of human health.

The Melanoma Research Alliance supports ambitious and innovative projects from both individual scientists and research teams to develop novel diagnostic and therapeutic avenues relevant to pathways governing the behavior and clinical outcome of melanoma. Read more about the CollabRx melanoma virtual biotech.

As the nation's largest philanthropy devoted exclusively to eradicating lung cancer, Bonnie J. Addario Lung Cancer Foundation (BJALCF) works with a diverse group of physicians, organizations, and individuals to identify solutions and make timely and meaningful changes through research, early detection, education, prevention, and treatment. Read more about how CollabRx has partnered with the Bonnie J. Adario Lung Cancer Foundation.

The Lymphangioleiomyomatosis (LAM) Treatment Alliance is dedicated to sponsoring and promoting research into LAM with the goal of finding a treatment for the disease in time for women living with the disease today. CollabRx has worked with the LAM Treatment Alliance to analyze current LAM research paths and provide strategies for managing and funding the portfolio of promising research areas.

Dana's Angels Research Trust (DART) is a nonprofit organization founded by Phil and Andrea Marella to fund medical research, medical education, or medical or hospital care for the treatment or cure of Niemann-Pick Type C disease (NPC) or other similar genetic diseases. Read more about how CollabRx has partnered with SOAR-NPC.

The Hide and Seek Foundation is a community of people dedicated to finding treatments and cures for Lysosomal Diseases, including the Tay-Sachs and Niemann Pick diseases. Read more about how CollabRx has partnered with SOAR-NPC.

The Addi and Cassi Fund is a "donor directed" research fund that has been established within the framework of the Ara Parseghian Medical Research Foundation (APMRF) and was named for Addison and Cassidy Hempel, identical twins who were diagnosed with Niemann Pick Type C (NPC) disease. Read more about how CollabRx has partnered with SOAR-NPC.

Expression Analysis provides high quality microarray services and solutions, including experimental design consultation, biologic sample preparation, sample processing and statistical analysis services. Expression Analysis is recognized today as a market leader in microarray outsourcing for gene expression, genotyping, and resequencing analysis.